Numerous recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.
These are the latest CDC numbers for COVID-19 in the USA:
States with the highest number of COVID-19 deaths:
An observational study of patients with systemic autoimmune inflammatory rheumatic diseases (AIRD) who also had COVID-19 disease shows that AIRD increased the risk of hospitalization, but that the use of disease-modifying antirheumatic drugs (DMARDs) were not associated with hospitalization.
Since the start of the pandemic, my emotions have swung like the pendulum of the hydroxychloroquine efficacy/inefficacy for COVID-19 debate. The highs and lows can be extreme.
JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it.”.
Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.
A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.
The American College of Rheumatology (ACR) has issued a guidance document for rheumatologists and rheumatology health professionals to consider as practices, business and patient care begins to reopen in this next phase of the COVID-19 pandemic.
Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.
In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population.
According to a small, observational study out of UCLA published as correspondence in the NEJM on July 21, 2020, those with mild COVID-19 symptoms showed an approximate antibody half-life of 73 days.
The number of reporting cases of COVID-19 infection tends to underestimate the true prevalence of infection as only the more severe cases (e.g.,acute respiratory syndrome) get tested or go to the hospital.
Dr. John Cush RheumNow( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Vinay Prasad VPrasadMDMPH( View Tweet)
Links:
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
